Literature DB >> 23619054

Multiplex qPCR assay for ultra sensitive detection of JCV DNA with simultaneous identification of genotypes that discriminates non-virulent from virulent variants.

Caroline F Ryschkewitsch1, Peter N Jensen, Eugene O Major.   

Abstract

BACKGROUND: JC virus (JCV) is the etiologic agent for progressive multifocal leukoencephalopathy (PML), a demyelinating disease occurring in the brain of patients with underlying immune compromised states. All viable JCV genomes contain a conserved region in the T protein coding nucleotide sequence that when detected by PCR in CSF is a confirmatory diagnostic marker for PML along with clinical and neuroradiological evidence. The non-coding regulatory region (NCRR) is hypervariable, as evidenced by nucleotide sequence of the non-virulent variant, which is predominantly excreted in urine, versus that of virulent variants found in brain and CSF of PML patients. All variants can be found in blood.
OBJECTIVE: A single assay that quantifies and identifies JCV DNA in clinical samples and discriminates between variants has significant value to physicians and patients at risk for PML. STUDY
DESIGN: Separate primer pairs were tested together to quantitatively detect conserved viral DNA nucleotide sequence in patient samples, while simultaneously detecting the NCRR specific for the non-virulent variant.
RESULTS: In testing using control plasmids and patients' CSF, blood, and urine, PML patients predictably demonstrated the non-virulent, archetype NCRR in urine, but virulent NCRR variants in CSF and blood.
CONCLUSION: The JCV qPCR multiplex assay targets two regions in JCV genomes to simultaneously identify and measure viral DNA, as well as distinguish between variants associated with PML and those that are not. The multiplex results could signal risk for PML if patients are viremic with JCV variants closely associated with PML pathogenesis. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23619054      PMCID: PMC3698945          DOI: 10.1016/j.jcv.2013.03.009

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  18 in total

Review 1.  A classification scheme for human polyomavirus JCV variants based on the nucleotide sequence of the noncoding regulatory region.

Authors:  P N Jensen; E O Major
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

2.  Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy.

Authors:  S A Houff; E O Major; D A Katz; C V Kufta; J L Sever; S Pittaluga; J R Roberts; J Gitt; N Saini; W Lux
Journal:  N Engl J Med       Date:  1988-02-04       Impact factor: 91.245

Review 3.  Viral variant nucleotide sequences help expose leukocytic positioning in the JC virus pathway to the CNS.

Authors:  P N Jensen; E O Major
Journal:  J Leukoc Biol       Date:  1999-04       Impact factor: 4.962

4.  Isolation of a possible archetypal JC virus DNA sequence from nonimmunocompromised individuals.

Authors:  Y Yogo; T Kitamura; C Sugimoto; T Ueki; Y Aso; K Hara; F Taguchi
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

Review 5.  Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain.

Authors:  Michael W Ferenczy; Leslie J Marshall; Christian D S Nelson; Walter J Atwood; Avindra Nath; Kamel Khalili; Eugene O Major
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

6.  Rearrangements of archetypal regulatory regions in JC virus genomes from urine.

Authors:  H T Agostini; C F Ryschkewitsch; G L Stoner
Journal:  Res Virol       Date:  1998 May-Jun

7.  Factors contributing to the restricted DNA replicating activity of JC virus.

Authors:  K J Lynch; R J Frisque
Journal:  Virology       Date:  1991-01       Impact factor: 3.616

8.  Human polyomavirus JC virus genome.

Authors:  R J Frisque; G L Bream; M T Cannella
Journal:  J Virol       Date:  1984-08       Impact factor: 5.103

9.  Investigation of pre-diagnostic virological markers for progressive multifocal leukoencephalopathy in human immunodeficiency virus-infected patients.

Authors:  Mary K Grabowski; Raphael P Viscidi; Joseph B Margolick; Lisa P Jacobson; Keerti V Shah
Journal:  J Med Virol       Date:  2009-07       Impact factor: 2.327

10.  Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation.

Authors:  Chen S Tan; Bruce J Dezube; Parul Bhargava; Patrick Autissier; Christian Wüthrich; Janice Miller; Igor J Koralnik
Journal:  J Infect Dis       Date:  2009-03-15       Impact factor: 5.226

View more
  28 in total

Review 1.  Diagnostic assays for polyomavirus JC and progressive multifocal leukoencephalopathy.

Authors:  Martyn K White; Ilker K Sariyer; Jennifer Gordon; Serena Delbue; Valeria Pietropaolo; Joseph R Berger; Kamel Khalili
Journal:  Rev Med Virol       Date:  2015-12-14       Impact factor: 6.989

2.  Progressive multifocal leukoencephalopathy with extended natalizumab dosing.

Authors:  Laura E Baldassari; Stephen E Jones; David B Clifford; Robert J Fox
Journal:  Neurol Clin Pract       Date:  2018-06

3.  Lymphocyte gene expression and JC virus noncoding control region sequences are linked with the risk of progressive multifocal leukoencephalopathy.

Authors:  Leslie J Marshall; Michael W Ferenczy; Elizabeth L Daley; Peter N Jensen; Caroline F Ryschkewitsch; Eugene O Major
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

4.  Cerebellar manifestation of PML under fumarate and after efalizumab treatment of psoriasis.

Authors:  Muriel Stoppe; Eva Thomä; Uwe Gerd Liebert; Eugene O Major; Karl-Titus Hoffmann; Joseph Claßen; Florian Then Bergh
Journal:  J Neurol       Date:  2014-03-18       Impact factor: 4.849

Review 5.  Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies.

Authors:  Eric M L Williamson; Joseph R Berger
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 6.  Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.

Authors:  A Salmen; R Gold; A Chan
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

7.  Progressive multifocal leukoencephalopathy in Zambia is caused by JC virus with prototype regulatory region.

Authors:  Eugene Mubanga; Atiyah Patel; Omar K Siddiqi; Barbara A Hanson; Xin Dang; Shabir Lakhi; Gina Mulundu; Noemi Bender; Igor J Koralnik
Journal:  J Neurovirol       Date:  2019-04-26       Impact factor: 2.643

8.  Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project.

Authors:  Kenneth R Carson; Scott D Newsome; Ellen J Kim; Nina D Wagner-Johnston; Gloria von Geldern; Craig H Moskowitz; Alison J Moskowitz; Alain H Rook; Pankaj Jalan; Alison W Loren; Daniel Landsburg; Thomas Coyne; Donald Tsai; Dennis W Raisch; LeAnn B Norris; P Brandon Bookstaver; Oliver Sartor; Charles L Bennett
Journal:  Cancer       Date:  2014-04-25       Impact factor: 6.860

9.  Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Clemens Warnke; Gloria von Geldern; Philipp Markwerth; Thomas Dehmel; Robert Hoepner; Ralf Gold; Michael Pawlita; Tania Kümpfel; Mathias Mäurer; Martin Stangel; Florian Wegner; Reinhard Hohlfeld; Vera Straeten; Volker Limmroth; Thomas Weber; Derik Hermsen; Christoph Kleinschnitz; Hans-Peter Hartung; Mike P Wattjes; Anders Svenningson; Eugene Major; Tomas Olsson; Bernd C Kieseier; Ortwin Adams
Journal:  Ann Neurol       Date:  2014-05-08       Impact factor: 10.422

Review 10.  Progressive Multifocal Leukoencephalopathy in HIV-Uninfected Individuals.

Authors:  Deanna Saylor; Arun Venkatesan
Journal:  Curr Infect Dis Rep       Date:  2016-11       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.